Cas:95163-43-2 1-Trityl-1H-pyrazole manufacturer & supplier

Chemical Name:1-Trityl-1H-pyrazole

CAS.NO:95163-43-2

Synonyms:1H-Pyrazole, 1-(triphenylmethyl)-;1-Tritylpyrazole;1-Trityl-1H-pyrazole

Molecular Formula:C₂₂H₁₈N₂

Molecular Weight:310.392

HS Code:2933199090

Physical and Chemical Properties:

Melting point:202-204ºC

Boiling point:479.3±44.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.606

PSA:17.82000

Exact Mass:310.147003

LogP:5.05

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Pyrazole, 1-(triphenylmethyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Trityl-1H-pyrazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Trityl-1H-pyrazole Use and application,1H-Pyrazole, 1-(triphenylmethyl)- technical grade,usp/ep/jp grade.

Related News: Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. 1-Trityl-1H-pyrazole manufacturer After this long manufacturing process, it is purified until it reaches a very high degree of purity and finally becomes an API. 1-Trityl-1H-pyrazole supplier We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries. 1-Trityl-1H-pyrazole vendor The firm announced its own acquisition of California-based chemical, manufacturing and control (CMC) advisor Chamow & Associates back in January to bolster Alira’s biologics manufacturing, quality assurance and regulatory compliance business. Further yet, 12 months ago, Alira picked up French consulting firm Care Factory for its data science experts and electronic health record database knowledge. 1-Trityl-1H-pyrazole factory Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector.